Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07118254) titled 'A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Lubris Bio Pty Ltd
Condition:
Ocular Graft Versus Host Disease
Intervention:
Drug: rhPRG4 450ug/ml
Recruitment Status: Not recruiting...